Annals of the New York Academy of Sciences 1993: Vol 690 Index

11 Pages·1993·0.99 MB·English

Subject Index
-ALCtive specific immunotherapy melanoma
for colorectal carcinoma, 135-145 biochemical and molecular studies of,
of colon adenocarcinoma, 331 64-65
of Hodgkin’s lymphoma, 352-354 recognized by autoantibodies, 63, 190
of melanoma, 120, 147, 153-164, 167, 178, melanoma-associated, 121, 163, 194-1%
190, 204, 214 mimicry by anti-idiotypic antibodies,
Adenocarcinoma, colon, active specific 214-221
immunotherapy of, 331 pancarcinoma T/Tn, detects carcinoma,
Adenovirus, 14 355-357
Adjuvants shed antigens, 190
in breast cancer, 276-290 tissue-specific, and tolerance, 60
in experimental malaria and AIDS to cytolytic T lymphocytes, 113-118
vaccines, 268-273 tumor, 323-328
QS-21, 392-395 in breast cancer, 340-342
tumor vaccines with, 303 in humans, 27-29
AIDS vaccine tumor rejection, in colorectal carcinoma,
experimental, 265-274 135-145
progress in, 12-13 tumor-associated, immunization against,
Alpha-interferon augments tumor 337-339
immunogenicity, 388-391 tumor-specific, recognized by T cells, 301-302
ALVAC HIV recombinant vims, 295 viral, expression of, in EBV-infected cells,
Anti-antiidiotypic mAb and melanoma cell 86-89
binding, 398-401 Antiidiotype vaccine therapy for T-cell
Anti-idiotype vaccine in Hodgkin-associated lymphoma, 376-377
CD30 antigen, 352-354 Antiidiotypic antibodies as immunogens, 30,
Anti-idiotypic antibodies in antigen mimicry, 214, 352, 385
213-221 ASl, See Active specific immunotherapy
Antibodies Autoantibodies, 60-61
monoclonal, to gangliosides, 54-55 and autoreactive T cells in melanoma, 61
semm, to gangliosides, 52-54 recognizing melanoma antigens, 63
Antigenic mutations in tumor evasion of studies of, 62
immune response, 46-49 Autoantigens, recognition of, in melanoma,
Antigens 59-66
as targets for active immunization, 24- Autoimmune disease, 19-22
31 Autoimmunity, 3
carbohydrate, TA3-Ha tumor for analysis lessons from, 19-23
of, 73
carcinoembryonic, vaccinia vims
expressing, 370-373 B lymphocytes, tolerance within, 38-39
colon tumor-associated, 374—375 B-cell lymphoma, idiotype-specific vaccine in,
detected by immune responses in man, 51 385-387
differentiation, of melanocytes and B-cell tolerance, 37-38
melanoma, 62 B7 as costimulatory molecule, 30
Epstein-Barr vims, as targets for immune in tumor immunity, 225-229
attack, 86-% B7 gene introduced into tumor cells, 304-305
for tumor rejection, cancer immunotherapy Bacillus Calmette-Gudrin vaccine in colorectal
with, 115-118 carcinoma, 135-145
genetically modified, as immunogens, 29- BCG, See Bacillus Calmette-Gu^rin
30 Bcr-abl protein, immunity to, 107-109
HLA-A, melanoma cell vaccine expressing, Breast cancer
343-345 immunization in, 276-290
Hodgkin-associated CD30, anti-idiotype recurrence of, vaccine to prevent, 355-357
vaccine in, 352 tumor antigens in, 340-342
immunogenic tumor, in man, 50-55 Burkitt's lymphoma, 42
404 ANNALS NEW YORK ACADEMY OF SCIENCES
Cancer, See also Carcinoma Cytokine genes introduced into tumor cells,
breast 305-306
immunization in, 276-290 Cytolytic T ceUs, cloning of, 233
tumor antigens in, 340-342
colorectal, 334-335
immunotherapy Daudi, Burkin’s lymphoma-derived cell
using poxvirus vectors, 292-298 tine, 42
with antigens for tumor rejection, Dendritic cell immune response to B-cell
115-118 lymphoma, 382-384
of viral etiology, vaccines for, 311-319 Depigmentation in melanoma, 61
synthetic B human chorionic gonadotropin Detox
vaccine in, 358 and keyhole limpet hemocyanin in breast
Cancer Immunology Branch, NCI, on cancer cancer, 276-290
vaccines, 322-329 in advanced melanoma, 155-157
Cancer vaccine adjuvant, QS-21 as, 392-395 DNP vaccine therapy in melanoma, 148-149
Cancer vaccines, 322-329
design strategies, 190-191
Cancer viruses EbNA, 87-88, 90-91
in animals, 8 EBV, See also Epstein-Barr virus
in man, 9-14 EBV-associated malignancies and T-cell
Carcinoembryonic antigen, vaccinia virus surveillance, 93-%
expressing, 370-373 EBV-infected cells, T-cell surveillance of,
Carcinoma 89-92
breast, recurrent, vaccine to prevent, Effector T cells in tumor rejection, 26
355-357 Engineered vaccines, 244-253, 256-262,
colorectal, adjuvemt vaccination in, 360-362 301-308
monoclonal antibodies in, 337-339 Epitope selection and design of synthetic
renal cell, adjuvant immunotherapy in, vaccines, 256-262
367-369 Epstein-Barr virus, 13
Carcinoma-derived cell line, HLA expression antigens as tai^ets for immune attack,
in, 42-43 86-%
CEM"^ helper/inducer T cells and synthetic ras studies of, 318-319
peptides, 102-104
Cell-ba^d immunotherapy using poxvirus-
based vectors, 2St7-298 Clamma-interferon and interleukin-2 in
Cellular antigens in cancer host, recognition tumor immunity, 349-351
of, 59 Ganglioside expression
Cervical cancer vaccine, prospects for, 80-83 in melanoma, 396-397
Cervical carcinoma-derived cell line (Hela), in tumors, 51-52
typed, 45-46 Gangliosides
Chromosome 9p22-23 mapped to gp75 gene, as targets of immunotherapy, 204
66 monoclonal antibodies to, 5^55
Colon adenocarcinoma, active specific serum antibodies to, 52-54
immunotherapy of, 331 GD3-conjugate vaccines, immunogenic,
Colon tumor-associat^ antigen, 374-375 396-397
Colorectal carcinoma Gene coding antigens, 113
adjuvant vaccination in, 360-362 for lung tumor, 114-115
immunotherapy for, 135-145 Genetically engineered tumor vaccines,
monoclonal antibodies in, 334-335, 337-339 244-253, 256-262, 301-308
specific immunotherapy of, 364-366 Genital papillomavirus infections, immune
Colorectal carcinoma-derived cell lines, 43-46 response to, 80-83
Costimulation in tumor immunity, 225-229 Glycosylation
Costimulatory molecules aberrant, of PEM, 76-77
in immune response, 27, 29 of mucins, 69-71
in tumor immunity, 30 gp75 antigen
Cross-reactive idiotypes (CRIds), 22 as human homolog of mouse b locus
Cyclophosphamide in immunotherapy, 30 product, 65-66
SUBJECT INDEX 405
as melanosome membrane glycoprotein, 64 Interleukin-2
expression in melanocytic cells, 64 and gamma-interferon in tumor immunity.
of human melanoma cells, 63-64 349-351
gp75 gene, chromosomal mapping of, 66 transfection of tumors with, 346-348
lnterleukin-2-infected tumor cell vaccines, 331
Hapten-modified vaccine in melanoma. ICeyhole limpet hemocyanin plus Detox in
147-151 breast cancer, 27^290
Hela cell line, typed, 45-46
Hepatitis B vaccine, 10-12 f
Hepatitis C virus, 13, 318-319 l-^eukemia, feline, vaccines for, 9
HIV vaccine development, 257 Liver metastasis, immunotherapy with tumor
HLA expression in carcinoma-derived cell cells, 364-366
lines, 42-43 Lymphocytes in tumor rejection, 26-28
HLA phenotypes and melanoma Lymphoma
immunotherapy, 160-161 B-ceU
HLA-A antigens, melanoma cell vaccine dendritic cell immune response to.
expressing, 343-345 382-384
Hodgkin’s lymphoma, active specific idiotype-specific vaccine in, 385-387
immunotherapy of, 352-354 T-cell, antiidiotype vaccine therapy for.
HPV16 and immunity, 28-29 376-377
Lysates
allogeneic cell, in melanoma
I immunotherapy, 155-157
Udiotype-specific vaccine in B-cell viral, as therapeutic vaccines in melanoma.
lymphoma, 385-387 167-176
IgG antibody response to melanoma
gangUoside vaccines, 204-211 m m
Immune attack, EBV antigens as targets for. iTAalaria vaccine, experimental, 265-274
86-% Marek’s disease, vaccine for, 9
Immune response MCV, See Melanoma cell vaccine
antitumor, immune tolerance in, 302-303 Melanocytes, autoimmune response against.
to genital papillomavirus infections, 80-83 in melanoma, 61
Immune system, polymorphic epithelial mucin Melanoma
as target for, 71-72 active specific immunotherapy of, 120, 147,
Immune tolerance, 59-60 153-164, 167, 178, 190, 204, 214
Immunity, T-cell, to oncogenic proteins. and melanocytes, differentiation antigens
101-110 of, 62
Immunization antigen vaccine from shed antigens, 190-202
in breast cancer therapy, 342 antigens
in colorectal cancer, 33^335 biochemical and molecular studies of.
with monoclonal antibodies in cancer. 64-65
337-339 recognized by autoantibodies, 63
Immunogenicity, enhanced, genetic alteration autoantibodies and autoreactive T cells in.
of tumors for, 304 61
Immunotherapy cell vaccine
active vs passive, 244-253 augmenting T-cell response with, 343-345
adjuvant, in renal cancer, 367-369 for metastatic melanoma, 120-132
polymorphic epithelial mucin as taiget for. cells
(&-TJ binding parameters to, 398-401
specific, of colorectal carcinoma, 364-366 gp75 antigen system of, 63-64
with vaccinia virus expressing CEA, depigmentation in, 61
370-373 ganglioside vaccines, IgG antibody
Infections, genital papillomavirus, immune response to, 204-211
response to, ^83 melanocytes and melanosomes, 61-62
Infectious diseases, vaccines against, 3 prevention with vaccines, 201-202
406 ANNALS NEW YORK ACADEMY OF SCIENCES
recognition of autoantigens in, 59-66 Poxvirus vectors in cancer immunotherapy,
theraccine, allogeneic, 154-155 292-298
therapeutic vaccines in, 167-176 Proteins
vaccine, 147-151 cancer-specific, as tumor-specific antigens,
alpha-interferon and, 388-391 109
surrogate marker of efficacy for, 378-380 oncogenic, 101-110
vaccinia melanoma oncolysate for, 178-187
Melanoma-associated antigens, 180-181 Q
Melanosomes, biogenesis of, 64-65 S-21 isomers, adjuvant activity of,
Monoclonal antibodies 392-395
against tumor antigens in cancer, 337-339
and melanoma cell binding, 398-401
antiidiotypic, 216-218 If 05 mutations in tumors, 102
human, 62 Ras p21 protein antibody detected in colon
to gangliosides, 54-55 cancer, 105
Monoclonal antiidiotypic antibody in Ras peptide, tumors elicit T cells for, 105
colorectal cancer, 334—335 Ras peptide-specific T cells respond to
Mucin parent^ protein, 104
glycosylation of, 69-71 Ras proteins, immunity to, 102
in normal and malignant tissues, 71 Rejection antigens, tumor-specific, 25
molecule, T-cell recognition of, 231-241 Renal cancer, adjuvant immunotherapy in,
polymorphic epithelial 367-369
as target for immunotherapy, 69-77 Retroviruses, 12-13
in cancer patients, 72-73 Rodents, tumor rejection and immune
MUCl gene, human, transgenic mice response to PEM in, 73
expressing, 73-75
Mutations, antigenic, in tumor escape of
immune response, 46-49 Serum antibodies to gangliosides, 52-54
Sialyl-Tn, synthetic, and KLH plus Detox in
breast cancer, 276-290
^Jational Cancer Institute perspective on Simian immunodeficiency disease, vaccine
cancer vaccines, 322-329 for, 9
Newcastle-disease virus-modified autologous Simian immunodeficiency virus vaccine,
tumor cells, 364-366 experimental, 268-273
NYVAC HIV recombinant virus, 295 Simian virus 40 vaccine, 8-9
T
Oncogenes, mutated, in tumor rejection, 29 cells
Oncogenic proteins, T-cell immunity to, autoreactive, and autoantibodies in
101-110 melanoma, 61
CEM"^, and synthetic ras peptides, 102-104
cytotoxic, specific for ras peptides, 107
P21ras protein elicits immune T cells, 104 effector, in tumor rejection, 26
Pancarcinoma T/Tn antigen detects in melanoma cell vaccine, 343-345
carcinoma, 355-357 ras peptide-specific, respond to p21ras
Papillomavirus infections, genital, immune protein, 104
response to, 80-83 T lymphocytes recognize genes coding for
Papillomaviruses, 14 antigens, 113-118
causative role of, in human tumors, 28-29 T-cell costimulation in tumor immunity,
studies of, 317-319 225-229
PEM, See Polymorphic epithelial mucin T-ceU epitopes in synthetic vaccines, 258
Peptides, synthetic T-cell immunity to oncogenic proteins,
bind to ckiss I MHC molecules, 106 101-110
immunogenicity studies using, 75-76 T-cell lymphoma, cutaneous, antiidiotype
Polyclonal anti-idiotypic antibodies, 214-215 vaccine therapy for, 376
Polymorphic epitheU^ mucin T-cell recognition
as target for immunotherapy, 67-77 of mucin cDNA, 231-241
in cancer patients, 72-73 of tumor-specific antigens, 301-302
SUBJECT INDEX 407
T-cell surveillance for metastatic melanoma, 120-132
and EBV-associated malignancies, 93-% idiotype-specific, in B-cell lymphoma,
of EBV-infected cells, 89-92 385-387
T-cell tolerance, 35-37 in colorectal cancer, 135-145
TA3-Ha tumor for analysis of carbohydrate in Hodgkin-associated CD30 antigen,
antigens, 73 352-354
TGF-/3 producing tumors, transfection of, in human melanoma, 120, 147-151, 153,
with IL-2, 346-348 167, 178, 190, 204, 214
Thymus, antigenic selection in, 35, 39 melanoma
Tissue-specific antigens and tolerance, 60 and alpha-interferon, 388-391
Tolerance T-cell response augmented with, 343-345
and tissue-specific antigens, 60 therapeutic, for melanoma, 378-380
immune, 59-60 Vaccines
and ways to break it, 34-40 against cancer in animals, 8-9
Transfection of tumors elicits tumor rejection, antigen-specific, 307-308
346-348 cancer, 322-329
Transgenic mice, tolerance research with, for human cancer of viral etiology, 311-319
37-38 for malaria and AIDS, experimental,
Tumor antigens, 323-325 265-274
human, 27-29 ganglioside, in melanoma, 204-211
immunogenic, 59 GD3-conjugate, immunogenic, 396-397
in man, 50-55 genetically engineered, 244-253, 301-308
improving ceUular immunity to, 325-328 genetically modified, 306-307
in breast cancer, 340-342 melanoma, viral lysates in, 167-176
Tumor escape from immune response, 42—49 shed antigens, 190
Tumor immunity synthetic, epitope selection and design of,
and peripheral tolerance, 328-329 256-262
costimulation in, 225-229 tumor cell, in colon adenocarcinoma, 331
interleukin-2 and gamma-interferon in, vector-based, in cancer therapy, 292-298
349-351 viral, 6-18
regulation of, 27 with adjuvants, 303
Tumor immunogenicity, augmented, with Vaccinia melanoma cell lysates, immunization
alpha-interferon, 388-391 with, 167, 172
Tumor immunology, 24-30 Vaccinia melanoma oncolysate for melanoma,
as basis for vaccine development, 322-323 178-187
Tumor recognition and rejection, 2 Vaccinia virus
Tumor rejection antigens expression of tumor antigens, 293
cancer immunotherapy with, 115-118 recombinant, in tumor vaccines, 331
recognized by T cells, 114 specific immunotherapy with, 370-373
Tumor vaccines overview, 1-5 Viral antigen expression in EBV-infected
Tumor vaccinology, foundations of, 4-5 cells, 86-89
Tumor-associated antigens, mimicry of, Viral etiology of human cancers, 311-312
214-221 Viral lysates in treatment of melanoma,
167-176
Viral vaccines against cancer, 6-18
accina virus expression of cytokines, Virus
293-294 nonpropagable, 7
Vaccination, adjuvant, in colorectal propagable, 7
carcinoma, 360-362 recombinant vaccinia, immunotherapy with,
Vaccine 370-373
antiidiotype, for cutaneous T-cell Virus-induced tumors, 25
lymphoma, 376-377 VMCL, See Vaccinia melanoma cell lysates
chorionic gonadotropin, in metastatic VMO, See Vaccinia melanoma oncolysate
cancer, 358-359
for melanoma prepared from shed antigens,
190-202 ?^enobiotics in autoimmunity, 20

Index of Contributors
E.
Abrams, S., 370-373 /ddy, G. A., 265-275
Aldrich, W., 358-359 Elashoff, R., 120-134
Alving, C. R., 265-275 Elliott, G. T., 378-381
Arlen, M., 374-375 Elliott, R. L., 340-342
Armbruster, C., 360-363
Austin, F. C., 322-330
r agerberg, J., 337-339
Famatiga, E., 120-134
Bash, J. A., 331-333 Favaro, D., 367-369
Baurain, J.-F., 113-119 Ferrone, S., xi, 214-224, 398-401
Bedore, D. A., 392-395 Fiaccavento, G., 367-369
Berd, D., 147-152 Finerty, J. F., 322-330
Berzofsky, J. A., 256-264 Finn, O. J., 231-243
Beverley, P., 69-79 Flamand, V., 382-384
Bicknell, D. C., 42-49 Foon, K. A., 376-377
Bloemena, E., 135-146 Foshag, L. J., 120-134, 343-345
Bodmer, J. G., 42-49 Francini, M., 367-369
Bodmer, W. F., 42-49 Frelinger, J., 346-348, 349-351
Boon, T., 113-119 Frodin, J.-E., 337-339
Bouchard, B., 59-68
Browning, M. J., 42-49
Burchell, J., 69-79 Galligioni, E., 367-369
Bystryn, J.-C., xi, 190-203 Gavioli, R., 86-100
Gissmann, L., 80-85
Calves, M., 396-397 Gochnour, D., 358-359
Campbell, M., 385-387 Goedegebuure, P., 153-166
Carbone, A., 367-369 Groshen, S., 153-166
Carmignani, G., 367-369 Gruber, J., 311-321
Chang, C., 120-134 Gupta, R. K., 120-134
Chapman, P. B., 59-68
Chatteijee, M., 376-377 rianna, M. G., Jr., 135-146
Cheever, M. A., 101-112 Hara, 1., 59-68
Chen, L., 225-230 Harel, W., 153-166
Chen, W., 101-112 Harkins, S., 349-351
Chen, Z. J., 398-401 Hart, S., 385-387
Cole, J. S., Ill, 311-321 Hayashi, Y., .343-345
Coulie, P., 113-119 Head, J. F., 340-342
Cox, W. I., 292-300 Heath, A. K., 322-330
Czerwinski, D., 385-387 Helling, F., 3%-397
Hellstrom, I., 24-33, 225-230
Dal Bo, V., 367-369 Hellstrom, K. E., 24-33, 225-230
de Campos-Lima, P. O., 86-100 Herman, J., 113-119
Denton, G. W. L., 334-336 Hersey. ?., 167-177
Depisch, D., 360-363 Hilleman, M. R., 6-18
Desai, P. R., 355-357 Hofbauer, F., 360-363
Detrick, B., 265-275 Hofman, F., 153-166
Di Donna, D., 367-369 Hollinshead, A. C., 374-375
Diehl, V., 352-354 Hoon, D. S. B., 120-134, 343-345
Dinstl, K., 360-363 Hoover, H. C., Jr., 135-146
Disis, M. L., 101-112 Houghton, A. N., 59-68
Dolcetti, R., 86-100 Hsu, F. J., 385-387
Domenech, N., 231-243 Huang, X.-Q., 153-166
Durrant, L. G., 334-336 Hutter, E., 346-348, 349-351
409
410 ANNALS NEW YORK ACADEMY OF SCIENCES
Irie, R. F., 120-134 Oettgen, H. F., 3%-397
Irvine, K., 370-373 Oseroff, A., 376-377
vFochmus, I., 80-85 Paoletti, E., 292-300
Pardon, D. M., 301-310
ICan-Mitchell, J., 153-166 Patel, B. T., 364-366
Kantor, J., 370-373 Peace, D. J., 101-112
Kaufman, H., 370-373 Perez, J., 378-381
Kensil, C. R., 392-395 Peters, L., 135-146
Koeppen, H., 244-255 Pfreundschuh, M., 352-354
Koganty, R., 276-291 Pohl, C., 352-354
Kohler, H., 376-377 Politzer, P., 360-363
Krausa, P., 42-49 Pomato, N., 135-146
Kwak, L., 385-387 Presant, C., 388-391
Pulaski, B., 346-348, 349-351
Lehmann, F., 113-119
LeMay, L. G., 153-166 Quaia, M., 367-369
Leo, 0., 382-384
Lespagnard, L., 382-384 ]R.agnhammar, P., 337-339
Levy, R., 385-387 Rainer, H., 360-363
Lewis, M. G., 265-275 Ransom, J. H., 135-146
Liebrich, W., 364-366 Rao, R., 388-391
Liles, T., 385-387 Reddish, M., 276-291
Linsley, P., 225-230 Renner, C., 352-354
Livingston, P. 0., xi, 1-5, 204-213, 396-397 Richards, R. L., 265-275
Lloyd, K. 0., 50-58 Robins, R. A., 334-336
Locker, G., 360-363 Rowan, A., 42-49
Longenecker, B. M., 276-291 Russell, D., 376-377
Lord, E., 346-348, 349-351
Sacco, C., 367-369
MacLean, G. D., 276-291 Santarosa, M., 367-369
Magarian-Blander, J., 231-243 Scanlon, E. F., 355-357
Maguire, H. C., Jr., 147-152 Schiessel, R., 360-363
Martin, E. W., 358-359 Schirrmacher, V., 364-366
Mastrangelo, M. J., 147-152 Schlag, P., 364-366
Masucci, M. G., 86-100 Schlom, J., 370-373
Mazza, G., 367-369 Schreiber, H., 244-255
McAdam, A., 346-348, 349-351 Schulte-Hermann, R., 360-363
McCoy, J. L., 340-342 Shafferman, A., 265-275
McLeod, R. A., 378-381 Shang, Y., 3%-397
Mellstedt, H., 337-339 Shen, G. L. C., 322-330
Miller, R., 385-387 Singh, S., 244-255
Mitchell, M. S., 153-166 Sivanandham, M., 178-189
Morisaki, T., 343-345 Smith, J., 388-391
Morton, D. L., 120-134, 343-345 Snoy, P., 370-373
Moser, M., 382-384 Sogn, J. A., 322-330
Mrozek, E., 376-377 Soltysik, S., 392-395
Muller, C., 113-119 Spada, A., 367-369
Muller, M., 80-85 Spencer, B. D., 355-357
Springer, G. F., 355-357
Naftzger, C., 59-68 Steinitz, M., 337-339
Nindl, I., 80-85 Stewart, L., 69-79
Nizze, A. J., 343-345 Stoeck, M., 364-366
Nizze, J. A., 120-134 Stoll, H., 376-377
Nossal, G. J. V., 34-41 Syrengelas, A., 385-387
INDEX OF CONTRIBUTORS 411
Vetterlein, M., 360-363
Takahashi, M., 101-112 Viggiano, S., 367-369
Talal, N., 19-23 Vijayasaradhi, S., 59-68
Talamini, R., 367-369 Von Eschen, K. B., 378-381
Tartaglia, J., 292-300
Taylor-Papadimitriou, J., 69-79
Wagner, O., 360-363
Tegtmeyer, H., 355-357
Waldhor, T., 360-363
Thielemans, K., 382-384
Wallack, M. K., 178-189
Triozzi, P. L., 358-359
Wanek, L. A., 120-134
Trivedi, P., 86-100
Wang, F., 340-342
Tsang, K. Y., 374-375
Weynants, P., 113-119
Wigzell, H., 337-339
X_Jchiyama, A., 343-345 Williams, T., 388-391
Ulsperger, E., 360-363 Wiseman, C., 388-391
Urbain, J., 382-384 Woods, F. M., 346-348
Wunderlich, M., 360-363
Vaickus, L., 376-377
Vermorken, J. B., 135-146 Zhang, Q.-J., 86-100